Colon-Targeted LNP Development

Colon-Targeted LNP Development

We develop colon-targeted LNPs through pH-gated lipid design, colonic ligand functionalization, and oral-compatible formulation, covering everything from lipid synthesis and ligand conjugation to gastrointestinal stability testing and in vivo colonic delivery evaluation.

Colon-targeted LNPs are designed to carry nucleic acids, proteins, or small molecules through the stomach and small intestine and release them at the colonic mucosa. A conventional LNP optimized for intravenous use does not survive this journey: gastric acid changes its ionization state, bile salts strip lipids from the particle, digestive enzymes attack the lipid matrix, and the mucus layer blocks access to epithelial cells. Colon-targeted systems therefore combine three design layers — a lipid composition that resists the gastrointestinal environment, a release mechanism triggered by colonic pH or microbial enzymes, and a surface ligand that favors uptake by epithelial cells, macrophages, or gut-homing leukocytes.

BOC Sciences provides integrated targeted LNP development, covering ionizable lipid screening, colonic ligand synthesis, surface functionalization, payload encapsulation, oral dosage-form integration, and cellular and in vivo evaluation. We support mRNA, siRNA, miRNA, plasmid DNA, genome-editing, protein, and small-molecule payloads, with formulation strategies selected according to the target colonic cell population and the intended administration route.

Schematic Diagram of Colon-Targeted Lipid NanoparticlesColon-Targeted Lipid Nanoparticle Illustration

BOC Sciences Colon-Targeted LNP Development Services

Our services connect lipid chemistry, gastrointestinal barrier engineering, nanoparticle formulation, and biological evaluation in one development plan. A project can start from an existing LNP formulation, a candidate ligand, an enteric coating concept, or nothing more than a target cell population and a payload. We define the development scope according to where in the colon the payload should act and how the formulation will be administered.

Colon-Specific Lipid Design and GI-Stability Screening

We examine how ionizable lipid structure and supporting lipids influence particle integrity in gastric and intestinal fluids, and how they affect uptake once the particle reaches the colonic mucosa.

  • Ionizable Lipid Selection: Compare headgroup chemistry, apparent pKa, tail length, branching, asymmetric tails, and linker structures to balance endosomal escape against stability in bile-salt media. Our LNP ionizable lipid optimization services support structure-guided screening rather than trial-and-error substitution.
  • Membrane Rigidity and Lipid Saturation: Adjust phospholipid identity, cholesterol content, and acyl-chain saturation to slow lipid extraction by bile salts and lipases, while keeping the bilayer flexible enough for fusion and endosomal release.
  • Plant-Type Galactolipid Exploration: Evaluate galactolipid-containing compositions inspired by edible-plant lipid vesicles, which are chemically distinct from standard four-component LNP systems and interact differently with the colonic epithelium.
  • Structure–Stability Screening: Rank candidates by size, PDI, zeta potential, and payload retention after exposure to simulated gastric fluid, simulated intestinal fluid, and bile-salt medium, so that only GI-robust designs move forward.

Colonic Targeting Ligand Engineering and Surface Functionalization

We build the targeting layer around the cell population that actually needs the payload — absorptive epithelium, goblet cells, resident macrophages, or gut-homing leukocytes — because each requires a different recognition chemistry.

  • Receptor-Selective Ligands: Evaluate hyaluronic acid, folate, mannose, galactose, and peptide motifs against receptors that are upregulated in inflamed or transformed colonic tissue, including CD44, folate receptor α, and mannose receptor.
  • Protein and Antibody Display: Explore antibody fragments, single-domain antibodies, and recombinant ligand domains displayed on the particle surface, with attention to orientation, accessibility, and species cross-reactivity.
  • Conjugation and Density Control: Optimize linker chemistry, lipid anchors, ligand-to-lipid ratio, and post-insertion conditions through nanoparticle conjugation services, then verify that the ligand remains exposed rather than buried in the PEG layer.

Oral-Compatible Payload Encapsulation and Dosage-Form Integration

An orally delivered LNP is only as good as the dosage form that carries it. We treat encapsulation, protective coating, and reconstitution behavior as one connected problem.

  • Payload-Specific Encapsulation: Tune lipid-to-payload ratio, aqueous and organic phase composition, mixing conditions, and formulation pH for each payload class through customized lipid nanoparticle formulation.
  • Protective Coating and Capsule Integration: Compare enteric polymer coatings, pH-responsive shells, and microparticle embedment, and define the pH or enzyme condition at which the payload should be released rather than relying on a single default trigger.
  • Drying, Storage, and Reconstitution: Assess lyophilization with cryoprotectant screening, resuspension behavior, and particle recovery, since a formulation that only survives as a refrigerated liquid limits oral dosing options.

Gastrointestinal, Cellular, and In Vivo Colonic Delivery Evaluation

We test the formulation in the sequence it will actually experience: stomach, small intestine, mucus layer, target cell, and tissue. Each step has its own readout, so a failure can be attributed to a specific barrier.

  • Biorelevant GI Exposure: Measure size, PDI, zeta potential, payload integrity, and functional activity after simulated gastric and intestinal incubation, including bile-salt and enzyme challenge.
  • Physicochemical Characterization: Quantify particle size distribution, surface charge, morphology, ligand density, and encapsulation efficiency using appropriate lipid nanoparticle characterization methods.
  • Colonic Cell Models: Compare uptake and functional delivery in Caco-2 and HT-29 epithelial models, mucus-producing co-cultures, and macrophage lines, with primary colonic cells added when the question requires it.
  • Tissue-Level Evaluation: Measure payload distribution across stomach, small intestine, colon, liver, and spleen through nanoparticle cellular and in vivo evaluation, and report colon-to-liver ratios instead of total signal alone.

Colon-Targeting Strategies for Lipid Nanoparticles

Colon targeting can be achieved by protecting the particle until it reaches the colon, by directing it to a specific colonic cell type, or by combining both. BOC Sciences supports lipid design, ligand synthesis, coating integration, formulation, and delivery evaluation across all four strategies below, so that the choice is driven by the payload and the target cell rather than by a fixed platform.

pH-Responsive LNPs for Gastric Protection and Colonic Release

pH-responsive LNPs keep the particle intact while gastric pH is low and release it once the environment becomes neutral to slightly alkaline in the distal intestine and colon. This is the most direct route to colonic exposure for oral dosing, and it is compatible with both liquid and solid dosage forms.

  • Design Approach: Apply enteric or pH-sensitive polymer coatings that stay insoluble below pH 5.5 and dissolve in the intestinal range. Screen coating thickness, plasticizer content, and shell-to-core ratio, then confirm release kinetics in simulated gastric and colonic media. Our pH-responsive lipid nanoparticles platform provides the starting architecture.
  • Use Scenarios: Oral siRNA or mRNA delivery to colonic epithelium and macrophages, repeated local dosing in chronic colitis models, and payloads that must avoid release in the small intestine.

Research basis: Reviews of colon-targeted oral delivery describe pH-gated coatings and capsules that protect nucleic acid carriers through gastric transit and release them in the colonic lumen (Journal of Controlled Release, 2023). Enzyme-cleavable linkers that respond to colonic microbiota provide a complementary trigger.

Ligand-Functionalized LNPs for Inflamed Colonic Cell Targeting

Ligand-functionalized LNPs add a recognition layer on top of tissue-level accumulation. In inflamed colon tissue, several receptors are consistently upregulated on activated macrophages, damaged epithelial cells, and gut-homing leukocytes, which makes receptor-mediated uptake a practical design target.

  • Design Approach: Compare CD44-directed hyaluronic acid-conjugated lipid nanoparticles, folate receptor-directed folate-conjugated lipid nanoparticles, and mannose receptor-directed mannose-conjugated lipid nanoparticles in the same assay format, then adjust ligand density to avoid masking by PEG.
  • Conformation- and Marker-Selective Targeting: For leukocyte-directed delivery, display recombinant integrin-binding domains or antibody fragments that recognize activation-dependent markers on gut-homing cells rather than markers expressed on all circulating T cells.
  • Use Scenarios: siRNA delivery to activated macrophages, mRNA expression in colonic epithelium, and payloads intended for a defined immune cell subset rather than bulk tissue.

Research basis: LNPs displaying the integrin-binding domains of a gut endothelial ligand targeted the high-affinity conformation of α4β7 integrin, silenced interferon-γ in the gut, and improved outcomes in experimental colitis without liver toxicity (Nature Nanotechnology, 2021).

Galactolipid LNPs for Biomimetic Colonic Accumulation

Some edible-plant lipid vesicles accumulate in the colon after oral administration, and their lipid profile can be reconstructed with defined components. This biomimetic route offers an alternative to polymer coatings for payloads that are sensitive to coating stress.

  • Design Approach: Rebuild plant-type lipid compositions from phosphatidic acid and mono- and digalactosyldiacylglycerol at defined molar ratios, then compare self-assembled particles with conventional four-component LNPs for size, charge, GI stability, and colonic accumulation. Our biomimetic-functionalized lipid nanoparticles capabilities support this line of work.
  • Use Scenarios: Oral mRNA delivery to colonic epithelium, payloads requiring a plant-lipid-like bilayer, and projects exploring membrane-derived or food-grade lipid concepts.

Research basis: Orally administered LNPs reconstituted from three ginger-derived lipids at a 5:2:3 ratio formed ~200 nm particles, raised IL-22 expression in colonic mucosa, and accelerated healing in a mouse colitis model (Biomaterials, 2022).

Mucoadhesive LNPs for Sustained Colonic Epithelial Residence

Mucus is the last barrier before the epithelium. Whether a particle should adhere to it or pass through it depends on the target: sustained residence favors local immune modulation, while rapid penetration favors epithelial uptake and transepithelial transport.

  • Design Approach: Tune surface charge, PEG density, and polymer coatings to shift behavior between mucoadhesion and mucus penetration. Charge-switchable lipid nanoparticles allow the surface to remain neutral in the gastric compartment and become adhesive only at colonic pH.
  • Use Scenarios: Extended local exposure in colitis models, M-cell and Peyer's patch-oriented delivery, and formulations where frequent dosing is impractical.

Research basis: Studies of oral nanocarriers consistently show that intermediate PEG surface density and near-neutral charge improve mucus transit, whereas strongly cationic surfaces are retained in the mucus layer.(Journal of Nanobiotechnology, 2022)

Which Colon-Targeting Strategy Fits Your LNP Project?

Tell us your payload, target colonic cell population, and dosing route. BOC Sciences can compare feasible strategies, synthesize the required lipids and ligands, and build a side-by-side evaluation plan.

Supported Payloads for Colon-Targeted LNPs

Colon delivery is not equally difficult for every payload. Nucleic acids need protection from nucleases in the gut lumen, proteins need mild loading conditions, and small molecules need retention during coating and drying. We match the loading route and the GI-protection architecture to the payload class.

Payload TypeSupported Uses & Colon-Targeted LNP Development ConsiderationsRequest Information
Colon-Targeted LNP for mRNAUsed for local expression of cytokines, tight-junction proteins, or reporter genes in colonic epithelium and macrophages. Development focuses on mRNA integrity after gastric exposure, encapsulation stability in bile-salt media, and expression restricted to the intestinal tract. Supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Colon-Targeted LNP for siRNAApplied to knockdown of pro-inflammatory mediators such as TNF-α, CD98, or MAP4K4 in colonic macrophages and epithelium. Key readouts are silencing in colonic tissue versus liver and spleen, payload retention during coating, and release at colonic pH, drawing on our lipid nanoparticles for siRNA delivery experience.Inquiry
Colon-Targeted LNP for miRNASuited to pathway-level regulation in intestinal inflammation and fibrosis, where a single miRNA can affect several mediators at once. Development considers duplex stability, loading ratio, and whether the mimic or inhibitor format changes the preferred lipid composition, supported by lipid nanoparticles for miRNA delivery.Inquiry
Colon-Targeted LNP for Cas9 mRNA and sgRNADesigned for local genome-editing research in colonic epithelium or immune cells, for example editing a cytokine gene in activated macrophages. Work covers co-loading of Cas9 mRNA and guide RNA, editing readouts in colonic cell models, and particle consistency across the coating step, using our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
Colon-Targeted LNP for pDNAUsed where a larger, more durable genetic unit is required, including reporter constructs and secretion cassettes. Development emphasizes condensation with cationic components, protection from shear during coating, and nuclear delivery in epithelial models, supported by lipid nanoparticles for pDNA delivery.Inquiry
Colon-Targeted LNP for Small MoleculeRelevant to poorly soluble anti-inflammatory and cytotoxic compounds that benefit from local exposure with reduced systemic burden. Formulation work covers drug–lipid compatibility, loading method, retention during enteric coating, and release profiling, supported by lipid nanoparticles for small molecule delivery.Inquiry
Colon-Targeted LNP for Protein and PeptideApplied to enzymes, cytokines, and peptide regulators intended for local intestinal activity. Development uses mild loading conditions, aggregation control, and activity assays after GI exposure, drawing on our protein encapsulation in LNPs experience.Inquiry
Colon-Targeted LNP for Fluorescent and Tracking LabelsSupports mapping of where particles go after oral dosing: gastric survival, small-intestinal loss, mucus retention, and colonic tissue accumulation. Labeled formulations are prepared so that the label does not alter surface properties, and imaging data are paired with quantitative tissue measurements.Inquiry
Colon-Targeted LNP for Custom PayloadFor co-delivery systems, unusual cargo, or early feasibility work. We evaluate payload compatibility, loading sequence, targeting modification route, coating tolerance, and performance in the agreed colonic models before committing to a formulation line.Inquiry
Need a Colon-Targeted LNP for Your Specific Payload?

Share your payload type, target cell population, and dosing route, and BOC Sciences will propose a loading and protection strategy that fits your project.

Our Colon-Targeted LNP Development Workflow

Projects begin with a target cell population and a route, not with a fixed formulation. We organize the work into four stages and revise the plan as gastrointestinal and biological data accumulate.

Project requirement discussion

1Define the Target Colonic Cell Population, Payload, and Route

We review the payload class, the intended colonic cell type — absorptive epithelium, goblet cells, macrophages, or gut-homing leukocytes — the administration route, and the biological readout that will define success. Route selection is treated as a design variable in its own right, as summarized in this guide to lipid nanoparticle administration route selection, because oral, rectal, and intravenous delivery impose different barriers on the same particle.

Lipid composition and targeting architecture selection

2Select Lipid Composition, GI-Protection Architecture, and Targeting Layer

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and a protection concept — enteric coating, pH-responsive shell, galactolipid composition, or microparticle embedment. Molar ratios are optimized through structured LNP lipid ratio optimization services, and every targeted design is paired with a matched non-targeted control so that the ligand contribution can be measured rather than assumed.

LNP formulation and characterization

3Formulate and Characterize Under Biorelevant GI Conditions

Candidates are prepared under controlled mixing, coated or encapsulated, and then tested in sequence: buffer, simulated gastric fluid, simulated intestinal fluid, and bile-salt medium. During LNP process optimization, we adjust lipid concentration, flow-rate ratio, coating thickness, purification, and buffer exchange, and advance only candidates that hold size, PDI, and payload retention within agreed limits at every stage.

Cellular and in vivo colonic delivery evaluation

4Evaluate Cellular and In Vivo Colonic Delivery

Selected candidates are tested in colonic epithelial and macrophage models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, target knockdown, or editing frequency, supported by nanoparticle cellular uptake testing. In vivo work then compares colonic tissue exposure against small-intestinal, hepatic, and splenic distribution, and findings are delivered as a comparative dataset with documented tradeoffs and recommended next experiments.

What Colon-Targeted LNP Development Challenges Do We Solve?

A colon-targeted LNP can look perfect in buffer and still deliver nothing to the colon. We separate the gastrointestinal, mucus, release, and cellular failure modes and test each one, so that the next iteration targets the step that is actually limiting performance.

✔ Gastric Acid, Enzymatic, and Bile-Salt Instability

Low pH alters the ionization state of the lipid, bile salts extract lipid from the particle, and lipases attack the lipid matrix. We test each condition separately rather than pooling them into one "GI stability" number, then adjust saturation, cholesterol content, and coating thickness accordingly. When instability dominates, lipid nanoparticle stability profiling under biorelevant media identifies which component is being lost.

✔ Mucus Entrapment and Limited Epithelial Access

A particle that adheres too strongly never reaches the epithelium, while one that repels mucus too completely may be cleared before it can be taken up. We measure mucus diffusion and epithelial uptake for the same batch, then tune surface charge and PEG density to reach the balance the target requires, using labeled particles to confirm where the population actually ends up.

✔ Premature Small-Intestinal Release or Hepatic Diversion

Releasing the payload too early wastes the dose before the colon, while intravenous routes tend to concentrate particles in the liver. We profile release across the pH range from stomach to colon through nanoparticle drug release profiling, and compare colonic release with hepatic accumulation so that the trigger condition can be moved rather than guessed.

✔ Poor Cell-Type Selectivity and Endosomal Retention

Uptake by the wrong cell type, or uptake without cytosolic release, both read as "no effect." We compare ligand density and receptor expression across the relevant colonic cell populations, and pair uptake data with LNP endosomal escape evaluation so that a post-uptake block is identified before the formulation is redesigned.

Facing Low Colonic Exposure or Early GI Release?

Send us your lipid composition, coating concept, payload, and the results you already have. BOC Sciences can isolate the limiting barrier and propose a focused comparison study.

Applications of Colon-Targeted LNPs

Colon-targeted LNPs are used wherever local intestinal exposure matters more than systemic circulation: inflammatory bowel disease, colorectal cancer, intestinal fibrosis, and mucosal immune modulation. BOC Sciences supports formulation and evaluation work across these areas, from payload selection to colonic distribution studies.

01

Inflammatory Bowel Disease Research

  • Cytokine Silencing: Deliver TNF-α, CD98, or MAP4K4 siRNA to activated macrophages in the inflamed colon, with colonic tissue silencing compared against liver and spleen to confirm local restriction. Antibody- and ligand-directed systems have been used to reach Ly6C-positive inflammatory monocytes in colitis models.
  • Barrier and Repair Cytokines: Explore IL-10 or IL-22 mRNA to raise local cytokine levels in damaged mucosa. Orally administered IL-22 mRNA-LNPs increased colonic protein expression and accelerated healing in a mouse colitis model (Biomaterials, 2022).
  • Leukocyte-Directed Delivery: Target gut-homing leukocytes through activation-dependent integrin conformations, an approach that reduced colonic interferon-γ in experimental colitis (Nature Nanotechnology, 2021).
02

Colorectal Cancer Research

  • Receptor-Directed Nucleic Acid Delivery: Target CD44 with hyaluronic acid coatings or folate receptor α with folate ligands, both of which are enriched on colorectal tumor cells and cancer stem-like populations. Common payloads include KRAS, survivin, and SOX9 siRNA tested in HCT116 and HT-29 models.
  • Local Chemotherapy Exposure: Load poorly soluble cytotoxics into colon-released particles to raise mucosal exposure while limiting systemic distribution, with release profiling across gastric to colonic pH.
  • Combination Formats: Use lipid nanoparticles for co-delivery to combine a nucleic acid payload with a small molecule, where the two components have different loading locations and release requirements.
03

Intestinal Fibrosis and Barrier Repair Research

  • Anti-Fibrotic Silencing: Deliver siRNA or miRNA targeting TGF-β1, ROCK, or TWIST1 to intestinal fibroblasts and myofibroblasts, with collagen deposition and α-smooth muscle actin readouts in fibroblast–epithelial co-cultures.
  • Tight-Junction Restoration: Express claudin or occludin constructs locally to study barrier recovery, where expression restricted to the colonic epithelium is the main design constraint.
  • Chronic Dosing Feasibility: Evaluate whether a coated oral formulation maintains particle quality and payload retention across repeated administration, since fibrosis models require extended timelines.
04

Oral Mucosal Immunomodulation and Vaccine Research

  • Gut-Associated Lymphoid Tissue Targeting: Design particles that interact with M cells overlying Peyer's patches or with lamina propria antigen-presenting cells, using lipid nanoparticles for antigen delivery as the formulation base.
  • Local Cytokine Expression: Combine antigen-encoding and immunomodulatory mRNA in one particle to study how local expression shapes mucosal immune responses.
  • Tolerance and Microbiome Studies: Investigate how colonic delivery of defined payloads alters local immune tone and microbial composition, an area where release location strongly affects the observed outcome.
Develop a Colon-Targeted LNP for Your Research Application

Tell us your intended application and the barrier you have already run into. BOC Sciences can design, synthesize, formulate, and evaluate colon-targeted LNPs around your project rather than around a fixed catalogue.

Why Choose BOC Sciences for Colon-Targeted LNP Development?

Lipid Materials and Colon-Targeting Ligand Supply

Ionizable lipids, PEG-lipid anchors, galactolipid components, and targeting ligands are sourced through our own material routes rather than assembled from unrelated suppliers, so formulation and material supply move on the same timeline and stay consistent between batches.

Rapid Project Response and Dedicated Technical Communication

Each project has a named technical contact who reviews the data with you directly. Feasibility feedback comes back quickly, and formulation adjustments are discussed against your readouts rather than delivered as a report after the fact.

Custom Lipid and Ligand Synthesis Design

When a published structure does not fit your target cell or route, we design and synthesize the ionizable lipid, linker, or ligand that does. This keeps the chemistry responsive to the biology instead of forcing a project onto an existing catalogue item.

Flexible Staged Collaboration Across Development Phases

Work can be scoped as a single stage — lipid synthesis, ligand conjugation, encapsulation, coating, GI stability testing, or in vivo distribution — or as a full program. Teams with existing capabilities can fill only the gap they have, and expand the scope when results justify it.

Integrated Colon Delivery Evaluation Platform

Simulated gastric and intestinal exposure, mucus and epithelial uptake, macrophage delivery, endosomal escape assessment, and in vivo colonic distribution are run within one platform, so results are directly comparable across candidates and across iterations.

FAQs

How do LNPs survive gastric acid and reach the colon?

Oral colon-targeted LNPs must withstand gastric acid (pH 1–2.5), bile salts, pancreatic lipase, and the overlying mucus barrier before reaching the colonic lumen. Protection is typically engineered on two levels: a pH-responsive enteric shell that stays intact below pH ~6 and dissolves only in the terminal ileum and colon, and an intrinsically robust lipid core, achieved through bile-salt-tolerant ionizable lipids and cholesterol-rich helper lipid ratios that slow enzymatic erosion. At BOC Sciences, every candidate formulation is challenged in simulated gastric and fasted-state intestinal biorelevant media, with size, encapsulation retention, and release-onset endpoints quantified before any in vivo work is initiated.

Inflamed colonic tissue overexpresses several addressable markers, each mappable to a ligand class: CD44 on activated epithelial and cancer cells, targeted with hyaluronic acid coatings; folate receptor-α on activated macrophages, captured by folate-conjugated PEG anchors; mannose receptors on macrophages and dendritic cells; MAdCAM-1 on gut-homing vasculature, recognized by conformation-sensitive ligands binding high-affinity α4β7 integrin; and Ly6C on inflammatory monocytes. The optimal ligand depends on the disease model and target cell population. BOC Sciences maintains a ligand panel covering these targets and runs comparative uptake screening in Caco-2, HT-29, HCT116, and macrophage models to identify the best-matching surface chemistry for each project.

Yes. The main obstacles are gastric destruction, dilution along the small intestine, and competitive hepatic uptake after intestinal absorption. Effective oral siRNA-LNP designs typically combine a pH-responsive or biomimetic lipid shell for GI protection, a particle size window of roughly 100–200 nm for mucus diffusion, and macrophage-directed surface chemistry such as mannose ligands or galactolipid-rich biomimetic membranes. In one BOC Sciences project, an oral TNF-α siRNA formulation screened across twelve ionizable lipids and four GI-protection architectures achieved approximately four-fold higher colonic siRNA exposure than the parenteral-reference composition in a DSS colitis model, with TNF-α expression in colonic tissue correspondingly suppressed.

Colon-targeted LNPs accommodate a broad payload range: siRNA and miRNA for gene silencing in epithelial or immune cells; mRNA encoding IL-10 or IL-22 for local immunomodulation; Cas9 mRNA with sgRNA or pre-formed ribonucleoprotein complexes for genome editing; plasmid DNA; hydrophobic small molecules such as 5-aminosalicylic-acid derivatives or kinase inhibitors; peptides and proteins protected from proteolysis; and fluorescent or radiolabeled tracers for biodistribution mapping. Lipid charge ratio, buffer system, and loading chemistry are tuned per payload class, and co-encapsulation of a nucleic acid together with a small molecule within a single particle is also achievable through matched ionizable lipid selection.

Evaluation proceeds across three levels. First, biorelevant GI stability: sequential incubation in simulated gastric fluid (pH ~1.2) and bile-salt-containing intestinal medium, tracking particle size, encapsulation retention, and release onset. Second, cellular assays: uptake, knockdown, and expression readouts in Caco-2, HT-29, HCT116, and Raw 264.7 macrophage models, complemented by endosomal escape assessment. Third, in vivo distribution: fluorescently labeled LNPs administered in DSS- or TNBS-induced colitis models, with colonic accumulation quantified against liver and small intestine by imaging and tissue analysis. BOC Sciences provides this entire evaluation chain as one integrated package, so all data sets are generated under directly comparable conditions.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code